L755507 is a novel, potent, and selective β3 adrenergic receptor (β3-AR) that can enhance CRISPR genome editing in pluripotent stem cells. It may also serve as a potential therapeutic target for the treatment of type II diabetes and obesity.
L755507 has been shown to enhance CRISPR genome editing efficiency. To see other small molecule CRISPR enhancers, visit
sigma.com/CRISPR-enhancers.
L755507 is a derivative of 4-acylaminobenzenesulfonamide.
Subnanomolar potent β 3 -adrenergic receptor partial agonist that is > 1000-fold selective over β 1 - and β 2 -adrenoceptors (EC 50 values are 0.43, 580 and > 10000 nM for activation of cloned human β 3 -, β 1 - and β 2 -adrenoceptors respectively). In vitro, stimulates lipolysis in rhesus adipocytes with an EC 50 of 3.9 nM.
L755507 is a potent β3-adrenergic receptor partial agonist with an EC50 value of 0.43 nM for β3 receptors with over 440-fold selectivity for β3 compared to β1 and β2-adrenergic receptor binding. L755507 has been shown to enhance CRISPR-mediated homology-directed repair (HDR) efficiency in human induced pluripotent stem cells (iPSCs), increasing the efficiency of GFP insertion by 3-fold compared to control cells.
l-755,507 displays an excellent activity profile as an extremely potent human β3 adrenergic receptor agonist (β3 ec50 0.43 nm), with >440-fold selectivity over β1 and β2 binding [1]. l-755,507 is also a potent and selective b3 partial agonist in rhesus monkeys as assessed by its affinity for the cloned b adrenergic receptors, and stimulates lipolysis in rhesus adipocytes with an ec50 = 3.9 nm [2].
dose rhesus monkeys with l-755,507 elicits lipolysis and metabolic rate elevation. the ed50 for glycerolemia was 0.03 mg/kg and the ed50 for tachycardia was 2.5 mg/kg, and stimulates metabolic rate by ~ 30% after acute bolus intravenous administration of 0.1 mg/kg [2].
13 nm (binding at the human β3 adrenergic receptor) [1]
[1] parmee er, ok ho, candelore mr, tota l, deng l, strader cd, wyvratt mj, fisher mh, weber ae. discovery of l-755,507: a subnanomolar human beta 3 adrenergic receptor agonist. bioorg med chem lett. 1998 may 5;8(9):1107-12.
[2] fisher mh, amend am, bach tj, barker jm, brady ej, candelore mr, carroll d, cascieri ma, chiu sh, deng l, forrest mj, hegarty-friscino b, guan xm, hom gj, hutchins je, kelly lj, mathvink rj, metzger jm, miller rr, ok ho, parmee er, saperstein r, strader cd, stearns ra, macintyre de, et al. a selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. j clin invest. 1998 jun 1;101(11):2387-93.